Skip to main content

InvestorNewsBreaks – Trxade Health Inc. (NASDAQ: MEDS) Announces Q1 2022 Financial Numbers, Operational Highlights

TRxADE Health (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States, has released its first quarter 2022 financial results. Highlights of the report, which covers the period ended March 31, 2022, include revenues for the period totaling $3.2 million, a 6% increase compared to the same quarter last year, and an uptick in the number of TRxADE platform registered users. The company reported 339 new registrations, compared to 223 for the same period in 2021; as of March 31, 2022, total registered users on the platform numbered 13,475, up from 12,560 on March 31, 2021. In addition, the company also announced a venture with SOSRx LLC, which has access to short-dated, overstock and slow-moving pharmaceuticals. “I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022,” said TRxADE Health CEO and chair Suren Ajjarapu in the press release. “We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities. Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication. . . . This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders.”

To view the full press release, visit

About TRxADE Health Inc

TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug procurement marketplace serving more than 13,475 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information about the company, please visit and

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.